Share this post on:

Product Name :
Brigatinib

Search keywords :
Brigatinib

drugId :
null

Target Vo:
Insulin-like growth factor I receptor

Target Vo Short Name :
IGF1R

Moa_Name:
Epidermal growth factor receptor erbB1 antagonists

First Approval Country :
United States

First Approval Date Filter:
2017

Origin Company_Name :
Ariad Pharmaceuticals Inc

Active Company_Name :
Ariad Pharmaceuticals Inc

Active Indication_Name:
Carcinoma, Non-Small-Cell Lung

In Active Indication_Name:
Myofibroma

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Sotigalimab Cancer
HDAC4 Rabbit mAb Technical Information
ICAM1 Antibody (YA352): ICAM1 Antibody (YA352) is a non-conjugated and Rabbit origined monoclonal antibody about 58 kDa, targeting to ICAM1. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human.

Share this post on:

Author: Interleukin Related